

References

- 1) Al-Ali HK, Stalbovskaya V, Gopalakrishna P, Perez-Ronco J, Foltz L. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. *Leuk Lymphoma*. 2016;57(10):2464-2467. doi:10.3109/10428194.2016.1146950
- 2) Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228. doi:10.1182/blood.2022015850
- 3) Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. *Leukemia*. 2019;33(8):1996-2005. doi:10.1038/s41375-019-0487-8
- 4) Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? *Blood*. 2017;130(2):115-125. doi:10.1182/blood-2017-04-742288
- 5) Bose P, Verstovsek S. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. *Cancer*. 2016;122(5):681-692. doi:10.1002/cncr.29842
- 6) ClinicalTrials.gov. A phase 3 study of pacritinib in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis (PACIFICA). Updated December 27, 2022. <https://clinicaltrials.gov/ct2/show/NCT03165734>
- 7) ClinicalTrials.gov. Study of oral navitoclax tablet in combination with oral ruxolitinib tablet when compared with oral ruxolitinib tablet to assess change in spleen volume in adult participants with myelofibrosis (TRANSFORM-1). Updated January 27, 2023. <https://www.clinicaltrials.gov/ct2/show/NCT04472598>
- 8) ClinicalTrials.gov. Study of oral navitoclax tablet in combination with oral ruxolitinib tablet to assess change in spleen volume in adult participants with relapsed/refractory myelofibrosis (TRANSFORM-2) Updated March 21, 2023. <https://www.clinicaltrials.gov/ct2/show/NCT04468984>
- 9) ClinicalTrials.gov. To evaluate the efficacy and safety of piasclisib and ruxolitinib in participants with myelofibrosis (LIMER-313). Updated December 5, 2022. <https://clinicaltrials.gov/ct2/show/NCT04551066>
- 10) ClinicalTrials.gov. To evaluate the efficacy and safety of piasclisib and ruxolitinib in participants with myelofibrosis who have suboptimal response to ruxolitinib (LIMER-304). Updated March, 2023. <https://clinicaltrials.gov/ct2/show/NCT04551053>
- 11) ClinicalTrials.gov. Phase 3 study of pelabresib (CPI-0610) in myelofibrosis (MF) (MANIFEST-2). Updated March 9, 2023. <https://clinicaltrials.gov/ct2/show/NCT04603495>
- 12) ClinicalTrials.gov. A study comparing imetelstat versus best available therapy for the treatment of intermediate-2 or high-risk myelofibrosis (MF) who have not responded to janus kinase (JAK)-inhibitor treatment. Updated March 15, 2023. <https://clinicaltrials.gov/ct2/show/NCT04576156>
- 13) ClinicalTrials.gov. KRT-232 versus best available therapy for the treatment of subjects with myelofibrosis who are relapsed or refractory to JAK inhibitor treatment (BOREAS). Updated March 1, 2023. <https://clinicaltrials.gov/ct2/show/NCT03662126>

- 14) ClinicalTrials.gov. Extension study of bomedemstat (IMG-7289) in patients with myeloproliferative neoplasms. Updated February 8, 2023. <https://clinicaltrials.gov/ct2/show/NCT05223920>
- 15) ClinicalTrials.gov. A study to evaluate safety and efficacy of selinexor in combination with ruxolitinib in participants with myelofibrosis. Updated January 31, 2023. <https://clinicaltrials.gov/ct2/show/NCT04562389>
- 16) ClinicalTrials.gov. Ruxolitinib phosphate and azacytidine in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Updated August 22, 2022. <https://clinicaltrials.gov/ct2/show/NCT01787487>
- 17) ClinicalTrials.gov. Combined ruxolitinib and enasidenib in patients with accelerated/blast-phase myelofroliferative neoplasm or chronic-phase myelofibrosis with an IDH2 mutation. Updated May 10, 2022. <https://clinicaltrials.gov/ct2/show/NCT04281498>
- 18) Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. *J Clin Oncol*. 2012;30(33):4098-4103. doi:10.1200/JCO.2012.42.3863
- 19) Essential Thrombocythemia Infographic. MPN Research Foundation. <http://www.mpnresearchfoundation.org/essential-thrombocythemia-infographic/>
- 20) Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. *Blood*. 2019;133(20):2233-2242. doi:10.1182/blood-2018-12-890889
- 21) Garmezy B, Schaefer JK, Mercer J, Talpaz M. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. *Blood Rev*. 2021;45:100691. doi:10.1016/j.blre.2020.100691
- 22) Gerds A, Mesa R, Vannucchi A, et al. Updated results from the momentum phase 3 study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. 64th ASH Annual Meeting and Exposition. Abstr 627. <https://ash.confex.com/ash/2022/webprogram/Paper162783.html>
- 23) Gerds AT, Savona MR, Scott BL, et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. *Blood Adv*. 2020;4(22):5825-5835. doi:10.1182/bloodadvances.2020003314
- 24) Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. *J Clin Oncol*. 2018;36(4):310-318. doi:10.1200/JCO.2017.76.4886
- 25) Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. *Haematologica*. 2016;101(12):e482-e484. doi:10.3324/haematol.2016.151449
- 26) Harrison CN, Gupta VK, Gerds AT, et al. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. *Future Oncol*. 2022;18(27):2987-2997. doi:10.2217/fon-2022-0484

- 27) Harrison CN, Garcia JS, Somerville TCP, et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients With myelofibrosis with progression or suboptimal response: phase II safety and efficacy. *J Clin Oncol*. 2022;40(15):1671-1680. doi:10.1200/JCO.21.02188
- 28) Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematol*. 2017;4(7):e317-e324. doi:10.1016/S2352-3026(17)30088-1
- 29) Harrison CN, Vannucchi AM, Kiladjan JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. *Leukemia*. 2016;30(8):1701-1707. doi:10.1038/leu.2016.148
- 30) Harrison C, Kiladjan JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med*. 2012;366(9):787-798. doi:10.1056/NEJMoa1110556
- 31) Inrebic. Prescribing information. Princeton, NJ: Bristol-Myers Squibb; October 2022.
- 32) Jakafi. Prescribing information. Wilmington, DE: Incyte; December 2022.
- 33) Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood*. 2014;123(14):2220-2228. doi:10.1182/blood-2013-11-537167
- 34) Mascarenhas J, Harrison CN, Gerds AT, et al. Safety analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. *Blood*. 2021;138(Suppl 1): 3640. doi:10.1182/blood-2021-151395
- 35) Mascarenhas J, Kremyanskaya M, Patriarca A, et al. MPN-375 BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis - JAK inhibitor-naïve or with suboptimal response to ruxolitinib - preliminary data from the MANIFEST study. *Clin Lymphoma Myeloma Leuk*. 2022;22 (Suppl 2): S335-S336. doi:10.1016/S2152-2650(22)01456-2
- 36) Mascarenhas J, Harrison CN, Kiladjan JJ, et al. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. *Future Oncol*. 2022;18(22):2393-2402. doi:10.2217/fon-2022-0235
- 37) Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. *JAMA Oncol*. 2018;4(5):652-659. doi:10.1001/jamaoncol.2017.5818
- 38) Mascarenhas J, Komrokji RS, Palandri F, et al. Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis. *J Clin Oncol*. 2021;39(26):2881-2892. doi:10.1200/JCO.20.02864
- 39) McFarland DC, Polizzi H, Mascarenhas J, Kremyanskaya M, Holland J, Hoffman R. Psychological symptoms among patients with BCR-ABL-negative myeloproliferative neoplasms. *J Natl Compr Canc Netw*. 2016;14(12):1563-1570. doi:10.6004/jnccn.2016.0168
- 40) Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. *Leuk Lymphoma*. 2014;55(3):595-600. doi:10.3109/10428194.2013.813500
- 41) Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. *Int J Hematol*. 2016;104(4):420-429. doi:10.1007/s12185-016-2084-1
- 42) Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international,

- randomised, phase 3 trial. *Lancet Haematol.* 2017;4(5):e225-e236. doi:10.1016/S2352-3026(17)30027-3
- 43) Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. *Hematology Am Soc Hematol Educ Program.* 2014;2014(1):287-296. doi:10.1182/asheducation-2014.1.287
- 44) Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. *Hematology Am Soc Hematol Educ Program.* 2017;2017(1):470-479. doi:10.1182/asheducation-2017.1.470
- 45) National Comprehensive Cancer Network. Myeloproliferative Neoplasms. Version 3.2022. Published August 11, 2022. Accessed January 22, 2023. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
- 46) Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. *JAMA Oncol.* 2015;1(5):643-651. doi:10.1001/jamaoncol.2015.1590
- 47) Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. *Leukemia.* 2017;31(12):2726-2731. doi:10.1038/leu.2017.169
- 48) Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. *Blood.* 2019;133(21):2348-2351. doi:10.1182/blood-2019-01-897637
- 49) Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. *Blood.* 2018;132(7):694-706. doi:10.1182/blood-2017-10-810739
- 50) Rumi E, Zibellini S, Boveri E, et al. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. *Am J Hematol.* 2019;94(7):E185-E188. doi:10.1002/ajh.25489
- 51) Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood.* 2011;118(2):401-408. doi:10.1182/blood-2011-01-328955
- 52) Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Adv.* 2016;1(1):21-30. doi:10.1182/bloodadvances.2016000216
- 53) Tremblay D, Mesa R, Scott B, et al. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. *Blood Adv.* 2020;4(23):5929-5935. doi:10.1182/bloodadvances.2020002970
- 54) Venugopal S, Mascarenhas J. Novel therapeutics in myeloproliferative neoplasms. *J Hematol Oncol.* 2020;13(1):162. doi:10.1186/s13045-020-00995-y
- 55) Verstovsek S, Chen CC, Egyed M, et al. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. *Future Oncol.* 2021;17(12):1449-1458. doi:10.2217/fon-2020-1048
- 56) Verstovsek S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *Leuk Lymphoma.* 2022;63:694-702. doi:10.1080/10428194.2021.1992756

- 57) Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med*. 2012;366(9):799-807. doi:10.1056/NEJMoa1110557
- 58) Yacoub A, Borate U, Rampal R, et al. MPN-075 efficacy and safety of add-on pascalisib to ruxolitinib therapy in myelofibrosis patients with low versus higher baseline platelet counts: A subgroup analysis of data from a phase 2 study. *Clin Lymphoma Myeloma Leuk*. 2022;22 (Suppl 2):S324. doi:10.1016/S2152-2650(22)01433-1
- 59) Yoon J, Pettit K. Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions. *Expert Rev Hematol*. 2021;14(7):607-619. doi:10.1080/17474086.2021.1944096